EMA panel recommendation for mCOMBRIAX approval sees Moderna stock fall 7.49%

Traders Union
All News
Companies
Moderna slides 7.49% to $49.56

Highlights

MRNA remains in a short-term downtrend, trading below major moving averages after a 7.49% intraday drop.
Indicators show mixed momentum, with oversold conditions and some underlying strength highlighted by strong weekly buy signals.
Price is expected to consolidate between $47.10 and $52.60 next week, with further downside limited by robust long-term support.

MRNA is trading at $49.56, which positions the stock below both the MA-20 ($53.11) and the Ichimoku Kijun ($53.82), but just above the MA-50 ($48.61). This pattern signals ongoing short-term and medium-term downward pressure but indicates longer-term structural support remains intact above the MA-200 ($33.09). The Ichimoku Kijun at $53.82 acts as immediate resistance above the current price. Near-term support is clustered at the MA-50 ($48.61), with key support located at the MA-100 ($38.64). Near-term resistance is at the MA-20 ($53.11), and key resistance sits at the Ichimoku Kijun ($53.82).

Momentum indicators on D1 present a mixed picture: MACD signals "Strong Buy," while ADX remains firm with a "Buy" rating, suggesting underlying strength despite the short-term pullback. The RSI at 46.07 and CCI at –104.52 both point to oversold conditions, which is echoed by the Stoch RSI at 0.00. BBP, however, signals overbought at 1.30, implying intraday buyer presence despite the session’s selloff. In today’s session, MRNA fell sharply by 7.49% from yesterday’s close, underlining a volatile and negative move. Over the past week, the stock declined by $1.82 (down 3.54%) compared with the previous week's close of $51.38. Price now sits at the very bottom of the weekly range, with weekly volatility standing at 10.46%. Current action represents a steady decline from the weekly high.

Looking forward, the expected price range for MRNA over the coming week is $47.10 to $52.60, aligning with typical weekly volatility and capturing the recent selloff within a realistic band. With three out of four weekly trend indicators (RSI-W1, ADX-W1, MACD-W1, MA-50-W1) showing a "Buy" or "Strong Buy" bias, the probability of a price increase is high (more than 80%), making further downside less likely. Baseline scenario: MRNA consolidates sideways between $47 and $52.60. Bullish scenario: a break above $52.60 could target higher resistance, capitalizing on the oversold readings. Bearish scenario: a close below $47.10 may trigger further selling, though strong long-term support lies above the 52-week low of $22.32. This outlook situates the forecast range well above the yearly low and below the recent 52-week high of $59.55.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Previously it was reported that Moderna’s stock was supported by underlying bullish momentum despite some near-term selling pressures and mixed technical signals. The current article adds a new dimension by examining recent developments that could drive renewed volatility, with traders advised to monitor emerging catalysts for shifts in the prevailing trend.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.